Seeking Alpha

An FDA Advisory Committee has voted unanimously in support of the use of Novartis' (NVS)...

An FDA Advisory Committee has voted unanimously in support of the use of Novartis' (NVS) Signifor, a treatment for patients with Cushing's disease who require medical therapeutic intervention. The drug is the first of its kind for this potentially debilitating endocrine disorder caused by a pituitary tumor that triggers excess cortisol. Phase III clinical trials showed patients who used Signifor experienced a rapid and sustained decrease in mean cortisol levels.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs